Abstract
Recent studies have demonstrated an association of glucagon-like peptide-1(GLP-1)signaling defect with non-alcoholic fatty liver disease(NAFLD). Native GLP-1 and GLP-1-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes, resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism, and the suppression of oxidative stress in liver cells. Moreover, GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD. (Chin J Endocrinol Metab, 2015, 31: 386-389) Key words: Non-alcoholic fatty liver disease; Glucagon-like peptide-1; Dipeptidyl peptidase-4
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
